Possible target indications incl Diabetes, Depression, Parkinson's, PTSD, & Schizophrenia based on "growing literature on cortisol-induced cognitive impairment" ans "existing data from earlier clincial programs" (refer 17 Oct pres). Huge markets beyond Alzheimer's, so this isn't a binary play come June next year. A preliminary decision on which of these to also develop is scheduled to be made in March. DYOR, GLTAH
Full page ad feature, page-5
Add ACW (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.6¢ |
Change
-0.001(3.70%) |
Mkt cap ! $76.57M | |||
| Open | High | Low | Value | Volume |
| 2.7¢ | 2.7¢ | 2.6¢ | $126.8K | 4.741M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 1312856 | 2.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.7¢ | 259595 | 2 |
View Market Depth
| Last trade - 16.10pm 14/10/2024 (20 minute delay) ? |
| ACW (ASX) Chart |